שווי מצרפי של נכסים: Acasti (ACST)

Acasti Pharma (ACST) is developing a long-term plan to expand therapy for rare neurovascular pathologies via the GTX system to strengthen its position in the med-heart sector. The business relies on creating improved modifications of known molecules to increase their bioavailability. Price action for the asset on GURU.Markets shows that total assets amount to 71.38, while the market currently prices in the risks associated with a small-cap biotech ahead of the completion of final clinical trials.

Total assets, reverse-calculated via ROA, reflect the aggregate resource potential of the business, where the historical trend of balance sheet assets allows for an assessment of capital management efficiency and debt load. For Acasti Pharma (ACST), this indicator is critical, as the material base depends directly on the success of clinical trials and the capitalization of the patent portfolio, determining the company's capacity for commercial scaling.